ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Bergapten exhibits antitumor effects on DMBA-induced oral squamous cell carcinoma via anti-inflammatory and apoptotic activities in hamsters by inhibiting NF-кB and PI3K/Akt/mTOR pathways.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Oral squamous cell cancer (OSCC) is a major cause of death in developing nations. Chemoprevention could be an effective approach for averting buccal mucosa carcinoma. Bergapten (BG) is a known furanocoumarin, a natural psoralen derivative extracted from several types of citrus and bergamot oil, which has exhibited anti-inflammatory, anticancer, and apoptotic properties. This current research investigates the chemopreventive efficacy of BG against 7,12 dimethylbenz(a)anthracene (DMBA)-induced hamster buccal pouch carcinogenesis (HBPC). OSCC was developed by painting DMBA (0.5%) in the HBP for 10 weeks and administering the effective dosages of BG (25 and 50 mg/kg bw) for 14 weeks. We investigate the tumor incidence, tumor burden, lipid peroxidation (LPO), antioxidants, xenobiotic enzymes, body weight changes, histopathological changes (H&E and PAS), immunohistochemistry, and quantitative real-time polymerase reaction (qRT-PCR) analysis. Administration of BG (25 and 50 mg/kg bw) dose-dependently inhibited (p < 0.05) tumor incidence and tumor burden and reversed the levels of the LPO, antioxidants, hepatic xenobiotic enzymes, body weight loss, and biochemical markers in the DMBA-stimulated hamsters. Furthermore, BG expressively elevated pro-apoptotic enzyme expressions (Bax, caspase-9, and caspase-3), while attenuating the B-cell lymphoma/leukemia type 2 (Bcl-2), inflammatory cytokines, and PI3K/Akt/mTOR signalling. These outcomes propose that BG employs chemopreventive and anticancer activity in DMBA-induced OSCC by triggering intrinsic apoptosis via repressing downstream inflammatory signalling cascades.
Indexed as
Identifiers
40699242What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.